PII (Pharmaceutics International) and Nexmed have signed a memorandum of understanding (MOU) for a strategic product development collaboration utilising Nexmed's Nexact drug delivery platform.
PII will promote the Nexact technology to its clients and may independently identify new product development opportunities for this collaboration.
PII will research and develop the pharmaceutical products with technical guidance and oversight from Nexmed.
It will also assume responsibility for clinical trial material manufacturing and commercial manufacturing of the new products.
The strategic goal of this agreement is to broaden the promotion of the Nexact technology platform and permit Nexmed access to PII's research and development and commercial manufacturing infrastructure.
